Figure 3: The identification of collagen type I⁺/CXCR4⁺ cells as FGF2-producing cells in the intrathoracic tumours produced by Y-MESO-14 cells.

(a) Representative images of tumour sections from mice treated with bevacizumab. FGF2 (green) was co-stained along with CD68, F4/80, Gr-1, collagen type I or CXCR4 (red). Scale bar, 100 μm. (b) Double staining of collagen type I and CXCR4 in tumours from mice treated with or without bevacizumab (bev). Scale bar, 200 μm. (c) The number of double-positive cells in the tumours was compared between the control- and bevacizumab (bev)-treated groups (n=20 per group). The data are shown as the means±s.e.m. *P<0.01 by the Mann–Whitney-U-test. (d) Representative images of double staining for collagen type I and CD45 in Y-MESO-14 tumours treated with bevacizumab. Scale bar, 100 μm. (e) Representative images of triple staining for collagen type I, CXCR4 and FGF2 in the tumours treated with bevacizumab. Scale bar, 50 μm. (f) Representative images of double staining for collagen type I (green) and CD68 or F4/80 (red) in Y-MESO-14 tumours treated with bevacizumab. Scale bar, 100 μm.